Join
Live feed
·
PRReleasevia Quantisnow
Applied Genetic Technologies Corporation logo

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

ByQuantisnow·Wall Street's wire, on your screen.
AGTC· Applied Genetic Technologies Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGTC (Applied Genetic Technologies Corporation) and more on Quantisnow.